title: Hormone therapy and different ovarian cancers: a national cohort study.
abstract: Postmenopausal hormone therapy use increases the risk of ovarian cancer. In the present study, the authors examined the risks of different histologic types of ovarian cancer associated with hormone therapy. Using Danish national registers, the authors identified 909,946 women who were followed from 1995-2005. The women were 50-79 years of age and had no prior hormone-sensitive cancers or bilateral oophorectomy. Hormone therapy prescription data were obtained from the National Register of Medicinal Product Statistics. The National Cancer and Pathology Register provided data on ovarian cancers, including information about tumor histology. The authors performed Poisson regression analyses that included hormone exposures and confounders as time-dependent covariates. In an average of 8.0 years of follow up, 2,681 cases of epithelial ovarian cancer were detected. Compared with never users, women taking unopposed oral estrogen therapy had increased risks of both serous tumors (incidence rate ratio (IRR) = 1.7, 95% confidence interval: 1.4, 2.2) and endometrioid tumors (IRR = 1.5, 95% confidence interval: 1.0, 2.4) but decreased risk of mucinous tumors (IRR = 0.3, 95% confidence interval: 0.1, 0.8). Similar increased risks of serous and endometrioid tumors were found with estrogen/progestin therapy, whereas no association was found with mucinous tumors. Consistent with results from recent cohort studies, the authors found that ovarian cancer risk varied according to tumor histology. The types of ovarian tumors should be given attention in future studies.
authors.affiliation: Gynecological Clinic, Copenhagen University Hospital, University of Copenhagen, Denmark. linamorch@yahoo.dk
authors.forename: Lina Steinrud
authors.initials: LS
authors.lastname: Mørch
authors.forename: Ellen
authors.initials: E
authors.lastname: Løkkegaard
authors.forename: Anne Helms
authors.initials: AH
authors.lastname: Andreasen
authors.forename: Susanne Krüger
authors.initials: SK
authors.lastname: Kjaer
authors.forename: Ojvind
authors.initials: O
authors.lastname: Lidegaard
mesh_terms: D000368:Aged; D018269:Carcinoma, Endometrioid / Q000139:chemically induced*; D015331:Cohort Studies; D003718:Denmark; D004334:Drug Administration Schedule; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004967:Estrogens / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000139:chemically induced*; D010051:Ovarian Neoplasms / Q000139:chemically induced*; D016012:Poisson Distribution; D011372:Progestins / Q000008:administration & dosage / Q000009:adverse effects; D012042:Registries; D012044:Regression Analysis; D012306:Risk
chemical_list: D004967:Estrogens; D011372:Progestins